IGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical Dispensaries
IGC’s Drug Candidate for Alzheimer’s Potentially Presents New Molecular Pathway for THC to Inhibit Aβ40 Production
IGC Builds Team Adding Industry Leader Dr. Chuanhai Cao, an expert on THC-Based Alzheimer’s Disease Treatments
IGC Featured in "Potential Blockbuster Treatment for Alzheimer's Disease Stands Out Among Medical Cannabis Companies"
IGC Appoints Medical Advisor Craig Cheifetz, M.D. to Consult on the Development of Cannabis- Based, Combination Therapies